120 related articles for article (PubMed ID: 1674871)
1. Effect of the calmodulin inhibitor trifluoperazine on phosphorylation of P-glycoprotein and topoisomerase II: relationship to modulation of subcellular distribution, DNA damage and cytotoxicity of doxorubicin in multidrug resistant L1210 mouse leukemia cells.
Ganapathi R; Kamath N; Constantinou A; Grabowski D; Ford J; Anderson A
Biochem Pharmacol; 1991 Jun; 41(12):R21-6. PubMed ID: 1674871
[TBL] [Abstract][Full Text] [Related]
2. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
Kamath N; Grabowski D; Ford J; Ganapathi R
Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806
[TBL] [Abstract][Full Text] [Related]
3. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R
Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.
Ganapathi R; Grabowski D
Biochem Pharmacol; 1988 Jan; 37(2):185-93. PubMed ID: 3342075
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
[TBL] [Abstract][Full Text] [Related]
6. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.
Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J
Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962
[TBL] [Abstract][Full Text] [Related]
7. Modulation of doxorubicin-induced chromosomal damage by calmodulin inhibitors and its relationship to cytotoxicity in progressively doxorubicin-resistant tumor cells.
Ganapathi R; Grabowski D; Hoeltge G; Neelon R
Biochem Pharmacol; 1990 Oct; 40(7):1657-62. PubMed ID: 2222519
[TBL] [Abstract][Full Text] [Related]
8. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
9. Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.
Ganapathi R; Schmidt H; Grabowski D; Melia M; Ratliff N
Br J Cancer; 1988 Sep; 58(3):335-40. PubMed ID: 3179186
[TBL] [Abstract][Full Text] [Related]
10. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H
Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
[TBL] [Abstract][Full Text] [Related]
11. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation.
Kawamura K; Grabowski D; Krivacic K; Hidaka H; Ganapathi R
Biochem Pharmacol; 1996 Dec; 52(12):1903-9. PubMed ID: 8951349
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
13. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline-induced DNA breaks and resealing in doxorubicin-resistant murine leukemic P388 cells.
Maniar N; Krishan A; Israel M; Samy TS
Biochem Pharmacol; 1988 May; 37(9):1763-72. PubMed ID: 2837239
[TBL] [Abstract][Full Text] [Related]
15. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity.
Covey JM; Kohn KW; Kerrigan D; Tilchen EJ; Pommier Y
Cancer Res; 1988 Feb; 48(4):860-5. PubMed ID: 2827887
[TBL] [Abstract][Full Text] [Related]
17. Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line.
Zalcberg JR; Hu XF; Wall DM; Mirski S; Cole S; Nadalin G; De Luise M; Parkin JD; Vrazas V; Campbell L
Int J Cancer; 1994 May; 57(4):522-8. PubMed ID: 7514153
[TBL] [Abstract][Full Text] [Related]
18. Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues.
Duran GE; Lau DH; Lewis AD; Kühl JS; Bämmler TK; Sikic BI
Cancer Chemother Pharmacol; 1996; 38(3):210-6. PubMed ID: 8646794
[TBL] [Abstract][Full Text] [Related]
19. Induced multidrug resistance in murine leukemia L1210 and associated changes in a surface-membrane glycoprotein.
Volm M; Bak M; Efferth T; Mattern J
J Cancer Res Clin Oncol; 1989; 115(1):17-24. PubMed ID: 2563999
[TBL] [Abstract][Full Text] [Related]
20. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]